Epeius Targeted Delivery System (TDS) and its pathotropic (or disease-seeking) properties, represents an enabling platform for the development of targeted molecular and genetic medicines. These proprietary biotechnologies can be adapted for the targeted delivery of a broad range of biopharmaceutical agents in vivo (in the body).
TDS Technology:Three separate and powerful components
Guidance System - A "pathotropic" or disease-seeking guidance system
Precision-targeted therapeutic gene delivery is accomplished by incorporating a physiological surveillance function inherent in von Willebrand coagulation factor - which is normally responsible for guiding platelets to exposed collagen in vascular wounds - into a nano-sized medicinal unit which then seeks out and accumulates in areas of significant tissue disruption, including primary and metastatic cancers. The surveillance function allows an anti-cancer agent to be administered intravenously, while it guides the anti-cancer agent (therapeutic nanoparticles) deep into tumors within minutes of infusion.
Stealth Nanoparticles - A stealth nanoparticle vehicle for therapeutic delivery
Highly-engineered retroviral vectors comprise the immunologically stealth therapeutic gene delivery vehicles (or vectors) of choice for cancer applications. Retroviral vectors, which are certifiably replication incompetent, have been shown to be safe in humans, but have been ineffective therapeutic gene delivery vectors due to the inherent, non-targeted nature of the standard vectors. Incorporating Epeius? guidance system into a state-of-the-art retroviral vector designs, has enabled the development of a powerful and precision-targeted gene therapy vector platform designed expressly for clinical applications.
Genetic Payload - Designer Anti-cancer Genes
In the Development of Rexin-G, scientists at Epeius Biotechnologies used their extensive working knowledge of cellular growth control mechanisms, cell cycle control enzymes, proto-oncogenes, and their executive functions in our cells to identify one of the most strategic and effective genetic loci that could be used to destroy tumor cells and their associated blood supply. Additional therapeutic genes that could be delivered with the benefit of pathotropic targeting include immune-activating cytokines for personalized cancer vaccinations (e.g., Reximmune-C) and reporter constructs that would target metastatic cancers and thereby improve cancer diagnostics and medical imaging with digital precision.